Artificial intelligence is recognized as a powerful tool for enhancing research and development of novel therapeutics. Machine learning and model training can be used to efficiently inform drug and device development. If AI or machine learning can improve the success or speed of the drug development process at any point, it would have big implications down the entire chain. This is a three-track event for pharmaceutical and healthcare professionals interested in improving health outcomes through and accelerating the availability of new treatments through the use of advanced technology.
Conference Early Bird Pricing - Register by April 26, 2019: USD 1495.0
Conference Standard Pricing - Register after April 26, 2019: USD 1695.0
Speakers: Pankaj Agarwal Senior Fellow, Computational Biology GLAXOSMITHKLINE, Ashish Atreja , M.D., MPH Assistant Professor and Chief Innovation Officer, Medicine ICHAN SCHOOL OF MEDICINE, MOUNT SINAI, NY, John Cai Executive Director, Real-World Data Analytics MERCK, Irene Choi, Ph.D. Director, Drug Discovery VERGE GENOMICS, Shaun Comfort Safety Science Principal Medical Director GENENTECH, Leslie Cousens Associate Director, Translational Medicine and Emerging Innovations ASTRAZENECA, Savan Devani Founder and CEO BIOTRILLION, Ronald Dorenbos Associate Director Materials and Innovation TAKEDA, Victoria Gamerman Head of U.S. Health Informatics and Analytics BOEHRINGER INGELHEIM, Alex (Wen-Yaw) Hsieh Director — Clinical Development Quality PFIZER, Kevin Hua Senior Manager A.I./Machine Learning Development BAYER